Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong · Delayed Price · Currency is HKD 40.44
-2.50 (-5.82%)
Oct 21, 2026, 2:45 PM HKT
Nanjing Leads Biolabs Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Nanjing Leads Biolabs stock has a consensus rating of "Strong Buy" and an average price target of $105.85. The average 1-year stock price forecast is 161.75% higher than the current stock price, while the lowest is $93.34 (+130.81%) and the highest is $117.49 (+190.53%).
Price Target: $105.85 (+161.75%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Sep 16, 2026.
Analyst Ratings
The average analyst rating for Nanjing Leads Biolabs stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Morgan Stanley No rating | Morgan Stanley | Buy Upgrades $79.00 → $93.00 | Buy | Upgrades | $79.00 → $93.00 | +129.97% | Sep 16, 2026 |
Unknown Analyst Shenwan Hongyuan No rating | Shenwan Hongyuan | Buy Maintains $108.89 | Buy | Maintains | $108.89 | +169.26% | Sep 11, 2026 |
Unknown Analyst SDIC Securities No rating | SDIC Securities | Buy Maintains $83.34 | Buy | Maintains | $83.34 | +106.08% | Sep 4, 2026 |
| CMB International Securities | CMB International Securities | Buy Reiterates $100.50 | Buy | Reiterates | $100.50 | +148.52% | Sep 3, 2026 |
Unknown Analyst CLSA No rating | CLSA | Buy Maintains $108.00 | Buy | Maintains | $108.00 | +167.06% | Jul 13, 2026 |
Financial Forecast
Revenue This Year
278.23M
from 177.26M
Increased by 56.96%
Revenue Next Year
416.32M
from 278.23M
Increased by 49.63%
EPS This Year
-0.95
from -1.03
EPS Next Year
-1.31
from -0.95
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.